Cyclica, a Toronto, Ontario, Canada-based in silico drug discovery company, completed a $2.4M Series A1 financing.
The round was led by GreenSky through the GreenSky Accelerator Fund I, LP, with participation from both existing and new investors including the China Canada Angel Alliance, and the family of Mr. Anthony Griffiths.
The company intends to use the funds to scale its sales and marketing efforts, and expand innovation through continued product development.
Led by Naheed Kurji, President and CEO, Cyclica offers a novel predictive analytics platform that enables the development of hypothetical, pre-clinical, clinical, or FDA-approved drugs. The company’s solution offers insight and analysis into a small molecule’s effect, in order to augment drug discovery pipelines and advance assets to-bedside. It currently features PROBEx (proteome-docking), SWITCHx (ligand effect prediction) & DIVEx (systems biology & drug-protein interactomes), and evaluates and compares small molecules to predict how each will interact with the human body (i.e human proteome).